BioAtla (NASDAQ:BCAB) Issues Earnings Results

BioAtla (NASDAQ:BCAB) announced its quarterly earnings data on Thursday. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.01, Zacks reports. During the same period last year, the business posted ($0.75) EPS.

BioAtla Price Performance

BCAB stock remained flat at $1.47 during midday trading on Friday. 467,416 shares of the company’s stock were exchanged, compared to its average volume of 679,873. The company has a market cap of $70.73 million, a P/E ratio of -0.59 and a beta of 1.06. The stock’s fifty day simple moving average is $1.57 and its 200-day simple moving average is $2.26. BioAtla has a 1 year low of $1.14 and a 1 year high of $4.02.

Wall Street Analyst Weigh In

Several research analysts have weighed in on BCAB shares. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of BioAtla in a research report on Wednesday, May 15th. JMP Securities dropped their price objective on BioAtla from $12.00 to $5.00 and set a “market outperform” rating for the company in a research report on Thursday, May 23rd.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.